Ginkgo Bioworks agreed to sell its biosecurity business to a consortium of investors in exchange for a minority equity stake in the standalone firm, and reported Q4 2025 revenue of $33.0 million—a 24% decline year‑over‑year. CEO Jason Kelly said spinning the biosecurity unit into a private company will allow it to access more targeted defense capital while Ginkgo focuses investment on autonomous lab automation and cell engineering. Ginkgo’s full‑year revenue fell 25% to $170.2 million and net loss narrowed to $312.8 million from a larger prior‑year loss. The company expects the divestiture to close in H1 2026 and emphasized it will remain commercially exposed to any upside through its retained minority stake. Business note: The move reflects ongoing portfolio reshaping by platform companies under capital constraints—selling non‑core or capital‑intensive units to specialized investors while concentrating on scalable platform offerings.